Joseph F. Goldberg, MD

Psychiatry leaders unpack pharmacogenetic testing hype, spotlight 4 actionable genes, and urge evidence-based use with therapeutic drug monitoring for personalized treatment.

Experts discuss rapid cycling and bipolar II, and weigh lithium as an often overlooked treatment option.

Joseph F. Goldberg, MD, urges evidence-based psychiatric deprescribing: continual med reviews, shared decisions, and smarter polypharmacy reduction.

Psilocybin therapy shows fast, lasting relief for depression; clinicians discuss trial hurdles and emerging promise for PTSD and addiction in this podcast.

HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.

HHS targets “psychiatric overprescribing,” but experts urge thoughtful deprescribing—stopping ineffective medications while replacing them with evidence-based alternatives tailored to patients.

Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast.

Clinicians explore neuroscience-guided off-label prescribing.

Explore GLP-1 agonists and their "truly transformative" role in psychiatry in this podcast.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

Learn why patients skip psych meds and how to boost adherence with stigma-free dialogue, routine hacks, family support, and deprescribing tips.

Learn more about the treatment of depression, selective serotonin reuptake inhibitors, and pregnancy in this podcast.

Psychiatry experts unpack why off-label medications are common and how evidence and dosing guide care.

New expert guidance shows how to safely review and taper psychiatric medications, weighing efficacy, risks, interactions, and patient input in mood disorders.

Experts discuss why early treatment and tailored combos can curb bipolar disorder.

Experts unpack child psychiatric medication: safety, early intervention, suicide risk, and managing side effects.

Explore the complexities of psychopharmacology in treating personality disorders, focusing on symptom management and the importance of therapeutic alliances.

Explore the complexities of pharmacogenetic testing in psychiatry, uncovering its current limitations and future potential in personalized medicine.

Learn more about the transformative potential of psychedelics in treating depression and mood disorders through expert insights and groundbreaking research.

Explore the intersection of psychotherapy and pharmacology in treating mood disorders, emphasizing personalized approaches for optimal patient outcomes.

What is the role of GLP-1 agonists in psychiatry? Joseph F. Goldberg, MD, and Roger S. McIntyre, MD, FRCPC, share their thoughts.

Read the full, exclusive transcript from the inaugural "Brain Trust: Conversations in Clinical Psychopharmacology" video with Joseph F. Goldberg, MD, and Marlene Freeman, MD.

In his brand new video series, Joseph F. Goldberg, MD, sits down with Marlene Freeman, MD, to discuss the issue of SSRIs and pregnancy.

Now more than ever, capturing and scaling the ingredients that make for compelling and impactful teaching for trainees is vital to our future.

In response to the threats associated with "DIY psychiatry," experts call for a renewed focus on collaboration and shared decision-making.

Deprescribing: a critical practice in medicine, emphasizing thoughtful medication management and patient-centered care for optimal health outcomes.

Joseph Goldberg, MD, discusses the recent joint statement on evidence-based medicine and psychotropic safety.

Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.

Joseph F. Goldberg, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

What are the key differences?